Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance

Summary

Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance (MONDO:0035764) is a disease. A subtype of idiopathic steroid-sensitive nephrotic syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 28

Clinical features

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO ID	Term	Frequency
HP:0000969	Edema	Very frequent (80-99%)
HP:0012592	Albuminuria	Very frequent (80-99%)
HP:0000097	Focal segmental glomerulosclerosis	Frequent (30-79%)
HP:0000282	Facial edema	Frequent (30-79%)
HP:0003073	Hypoalbuminemia	Frequent (30-79%)
HP:0003077	Hyperlipidemia	Frequent (30-79%)
HP:0010741	Pedal edema	Frequent (30-79%)
HP:0012378	Fatigue	Frequent (30-79%)
HP:0012622	Chronic kidney disease	Frequent (30-79%)
HP:0100540	Palpebral edema	Frequent (30-79%)
HP:0100724	Hypercoagulability	Frequent (30-79%)
HP:0000034	Hydrocele testis	Occasional (5-29%)
HP:0000822	Hypertension	Occasional (5-29%)
HP:0002027	Abdominal pain	Occasional (5-29%)
HP:0002094	Dyspnea	Occasional (5-29%)
HP:0002907	Microscopic hematuria	Occasional (5-29%)
HP:0003774	Stage 5 chronic kidney disease	Occasional (5-29%)
HP:0011947	Respiratory tract infection	Occasional (5-29%)
HP:0012393	Allergy	Occasional (5-29%)
HP:0012579	Minimal change glomerulonephritis	Occasional (5-29%)
HP:0001541	Ascites	Very rare (<1-4%)
HP:0002202	Pleural effusion	Very rare (<1-4%)
HP:0002204	Pulmonary embolism	Very rare (<1-4%)
HP:0004420	Arterial thrombosis	Very rare (<1-4%)
HP:0004431	Complement deficiency	Very rare (<1-4%)
HP:0004936	Venous thrombosis	Very rare (<1-4%)
HP:0012050	Anasarca	Very rare (<1-4%)
HP:0012587	Macroscopic hematuria	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance
Mondo ID	MONDO:0035764
Orphanet	567546
UMLS	C5680131
MedGen	1830098
GARD	0022286
Is cancer (heuristic)	no

Also known as: Idiopathic SSNS with secondary steroid resistance · Secondary SRNS · Secondary steroid-resistant nephrotic syndrome

Disease family

This is a subtype of idiopathic steroid-sensitive nephrotic syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › nephrotic syndrome › idiopathic nephrotic syndrome › idiopathic steroid-sensitive nephrotic syndrome › idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance

Related subtypes (3): idiopathic steroid-sensitive nephrotic syndrome with focal segmental hyalinosis, idiopathic steroid-sensitive nephrotic syndrome with minimal change, idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.